Table 2:
Results of Logistic Regression Models Predicting Adoption of Opioid Use Disorder Medications
| Oral Naltrexone (n=383) | Injectable Naltrexone (n=383) | Buprenorphine (n=397) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| AOR | 95% CI | p-value | AOR | 95% CI | p-value | AOR | 95% CI | p-value | |
| State Policy | |||||||||
| SSA block grant funding for medication | 3.14 | 1.49-6.60 | .004 | 1.44 | .66-3.16 | .350 | .54 | .27-1.11 | .093 |
| SSA subsidizes buprenorphine with state funds | -- | -- | -- | -- | 2.47 | 1.31-4.67 | .006 | ||
| SSA level of technical support | 1.13 | .88-1.46 | .332 | 1.25 | .94-1.65 | .115 | 1.18 | 1.00-1.39 | .049 |
| Control Variables | |||||||||
| Organizational Characteristics | |||||||||
| Program ownership | |||||||||
| Private non-profit (reference: private for-profit) | 3.59 | 1.40-9.20 | .009 | 1.17 | .34-4.06 | .789 | 2.56 | 1.09-6.02 | .032 |
| Public ownership (reference: private for-profit) | 3.07 | .74-12.69 | .117 | .60 | .10-.71 | .573 | 2.87 | .88-9.36 | .078 |
| Program type | |||||||||
| Inpatient/Residential (reference: outpatient) | 3.14 | 1.07-9.22 | .038 | 2.22 | 1.01-4.91 | .049 | 1.51 | .87-2.63 | .138 |
| Accredited by JC/CARF | 1.41 | .60-3.32 | .424 | 1.58 | .51-4.93 | .420 | 1.16 | .49-2.76 | .732 |
| Program size (number of clients served, log) | 1.24 | .91-1.69 | .176 | 1.06 | .74-1.50 | .759 | 1.53 | 1.21-1.94 | .001 |
| Staff professionalism | .53 | .11-2.65 | .428 | 3.74 | .65-21.52 | .135 | 1.18 | .27-5.09 | .817 |
| % private insurance revenues | 1.02 | .99-1.04 | .167 | 1.01 | .99-1.04 | .274 | 1.01 | .99-1.03 | .171 |
| Client socio-demographic characteristics | |||||||||
| % Black | .98 | .96-1.01 | .135 | .99 | .97-1.01 | .343 | .99 | .98-.00 | .183 |
| % Hispanic | .99 | .96-1.01 | .394 | 1.00 | .97-1.03 | .854 | 1.00 | .97-1.03 | .893 |
| % women | 1.01 | .99-1.02 | .259 | 1.00 | .98-1.03 | .692 | 1.00 | .99-1.01 | .903 |
| Market Factors | |||||||||
| Perceived increase in competition | 2.33 | 1.34-4.03 | .004 | .54 | .28-1.04 | .064 | 1.08 | .51-2.31 | .829 |
| % heroin clients | 1.00 | .98-1.02 | .661 | 1.02 | 1.01-1.04 | .013 | 1.01 | .99-1.02 | .057 |
| % prescription opioid clients | 1.00 | .98-1.03 | .689 | 1.00 | .97-1.02 | .784 | 1.01 | 1.00-1.02 | .146 |
Note: The number of programs and states included in multivariate analyses varies by medication, based on the amount of missing data.